Marketed By
bdr pharma
Pack of
60 Tablets in Bottle
Salt Composition
Rucaparib
Storage
Keep in Cold Place
Contact for Price
Bdparib 200mg Tablet
Delivering To: —
All Substitutes
Overview
The Bdparib 200 mg is a member of the class known as polyADP-ribose polymerase inhibitors. The active component of this anti-cancer medication is rucaparib. It is used to treat some forms of ovarian cancer, fallopian tube cancer (found in females), and primary peritoneal cancer (a layer of tissue lining the belly). In individuals with a certain gene mutation (BRCA), the bdparib 200mg is also used to treat some forms of cancer. Those who are allergic to Bdparib or any of its constituents should not take this cancer medication.
Indication
Ovarian Cancer, Prostate cancer
Uses
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Benefits
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Side Effects
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
How To Use
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
How It Works
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Safety Advice
Alcohol
CONSULT YOUR DOCTOR
Pregnancy
CONSULT YOUR DOCTOR
Breast Feeding
CONSULT YOUR DOCTOR
Driving
UNSAFE
Kidney
SAFE IF PRESCRIBED
Liver
SAFE IF PRESCRIBED
Missed Doses
Quick Tips
FAQs
As soon as you remember, take the missed dose unless it's time for your next dose. You should never take a double dose to make up for a missed one.
Common side effects of the Bdparib 200mg tablet are constipation, muscle pain, swelling, nausea, diarrhea, infection, loss of appetite, hair loss, vomiting, and weakness.
The doctor decides how long the treatment with the Bdparib 200mg tablet will continue, depending on the stage and health of the patient.
It is advised not to take alcohol while taking the Bdparib 200mg tablet, because consuming alcohol can cause serious side effects and can damage your liver badly. Consult your doctor if you have concerns or queries.
During pregnancy, it is not safe to take the Bdparib 200mg tablet, as it can cause harm to the unborn baby. Furthermore, during breastfeeding, this medicine must not be used. Please make sure to consult your healthcare provider regarding the same.
Bdparib 200 mg tablet blocks the androgen receptor due to the presence of enzalutamide. It blocks testosterone from reaching prostate cancer cells. Testosterone production helps cancer cells grow, so by blocking the generation of this hormone, the growth of cancer cells can be shrunk. Bdparib 200 mg tablet belongs to the androgen receptor inhibitors.
Inform the doctor if you are allergic to the ingredient present in the Bdparib 200 mg tablet, in case of high sugar level, pregnancy or breastfeeding, or a weakened immune system. A patient with a medical history or medication must discuss it with a doctor.
No, Bdparib 200mg tablet is an anti-cancer medication that contains enzalutamide, which is an androgen receptor inhibitor.
Bdparib 200 mg tablet blocks the androgen receptor due to the presence of enzalutamide. It blocks testosterone from reaching prostate cancer cells. Testosterone production helps cancer cells grow, so blocking its production can shrink cancer cell growth. Bdparib 200 mg belongs to the androgen receptor inhibitors.
Reference
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Ratings And Reviews
4.83/5
6 Ratings
5 Star
83.33%
4 Star
16.67%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
Mark T.
Good quality product
9 months ago
Gaurav J.
Highly recommended
a year ago
View All Reviews
Related Products
MARKETER DETAILS
bdr pharma
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.